REPLIMUNE GROUP INC (REPL)

US76029N1063 - Common Stock

12.49  +0.48 (+4%)

After market: 12.49 0 (0%)

News Image
a month ago - Replimune Group Inc

Replimune Announces Pricing of Upsized Public Offering

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of...

News Image
a month ago - Replimune Group Inc

Replimune Announces Proposed Public Offering

News Image
a month ago - Replimune Group Inc

Replimune Announces Proposed Public Offering

WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image
a month ago - Market News Video

Notable Friday Option Activity: NOW, VSH, REPL

News Image
a month ago - Replimune Group Inc

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image
a month ago - Replimune Group Inc

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus...

News Image
a month ago - Replimune Group Inc

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions...

News Image
a month ago - Replimune Group Inc

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image
2 months ago - Replimune Group Inc

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from...

News Image
2 months ago - Replimune Group Inc

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

News Image
3 months ago - Replimune Group Inc

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image
3 months ago - Replimune Group Inc

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and...

News Image
3 months ago - Replimune Group Inc

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

Aligned with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma...

News Image
4 months ago - Replimune Group Inc

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination...

News Image
5 months ago - InvestorPlace

REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025

REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025.

News Image
5 months ago - Replimune Group Inc

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H...

News Image
5 months ago - Replimune Group Inc

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image
6 months ago - Market News Video

REPL Crosses Above Key Moving Average Level

News Image
6 months ago - Replimune Group Inc

Replimune Announces $100 Million Private Placement Financing

- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional...

News Image
7 months ago - Replimune Group Inc

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image
7 months ago - Replimune Group Inc

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first...

News Image
7 months ago - Replimune Group Inc

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response...